Hyperprolactinemia: Causes, Clinical Features, and Treatment
Diagnosis
A single elevated serum prolactin measurement above the upper limit of normal confirms hyperprolactinemia, provided the sample was obtained without excessive venipuncture stress 1. Dynamic testing is not recommended 1.
Critical Diagnostic Considerations:
- Assess for macroprolactin in asymptomatic patients to avoid unnecessary treatment 1
- Check for "hook effect" when there's a discrepancy between a very large pituitary tumor and only mildly elevated prolactin—serial dilution of serum samples eliminates this immunoassay artifact that causes falsely low readings 1
Causes
Always exclude these four causes first in symptomatic patients: 1
- Medications (especially antipsychotics, antidepressants)
- Renal failure
- Hypothyroidism
- Pituitary and parasellar tumors
Prolactinomas
Prolactin levels generally parallel tumor size 1:
- Microadenomas: Mean ~99 µg/L (range 16-385 µg/L)
- Macroadenomas: Mean ~1415 µg/L (range 387-67,900 µg/L)
However, any prolactin level can occur with any tumor size 1.
Clinical Features
Prolactinomas cause galactorrhea, sexual dysfunction, and decreased bone density when gonadal steroids are reduced 1.
Gender-Specific Presentations:
Women:
- Galactorrhea (prevalence ~19-45%)
- Oligomenorrhea/amenorrhea (~45%)
- Infertility
- Low bone mass from hypogonadism
Men:
- Sexual dysfunction
- Hypogonadal symptoms
- Decreased bone density
Treatment Algorithm
For Symptomatic Prolactinomas (Micro- or Macroadenomas):
Start cabergoline as first-line therapy—it is superior to all other dopamine agonists 1. Cabergoline normalizes prolactin in 71-95% of patients and achieves tumor shrinkage in 80-92% 1.
Dosing:
- Start 0.25-1.0 mg twice weekly
- Most patients require 0.25-3 mg/week
- Occasional patients need up to 11 mg/week 1
Follow-up protocol:
- Measure prolactin monthly initially to guide dose titration
- Repeat MRI at 1 year (or 3 months for macroadenomas if prolactin rises or new symptoms develop)
- Visual field exams for macroadenomas near optic chiasm
- Assess bone density and sex steroid status 1
For Asymptomatic Microprolactinomas:
Do not treat with dopamine agonists 1. Microadenomas rarely grow 1.
Exception: If amenorrhea is present, offer either dopamine agonist OR oral contraceptives 1. Oral contraceptives are less expensive with fewer side effects, though amenorrhea won't indicate disease recurrence during treatment 1.
For Drug-Resistant Prolactinomas:
Escalate cabergoline dose to maximal tolerable levels before considering surgery 1.
If bromocriptine-resistant, switch to cabergoline 1.
Surgery is indicated only when:
- Patient cannot tolerate high-dose cabergoline, OR
- No response to dopamine agonist therapy 1
For intolerance to oral bromocriptine, try intravaginal administration before surgery 1.
Radiation therapy is reserved for patients who fail surgery or have aggressive/malignant prolactinomas 1.
Temozolomide for malignant prolactinomas 1.
Discontinuation Strategy:
Consider tapering dopamine agonists after ≥2 years of treatment if:
- Prolactin normalized, AND
- No visible tumor on MRI 1
Requires careful clinical and biochemical follow-up 1.
For Medication-Induced Hyperprolactinemia:
Step 1: Stop the offending drug if clinically feasible 1
Step 2: If stopping isn't possible, substitute with a drug that doesn't cause hyperprolactinemia 1
Step 3: If substitution isn't feasible, cautiously consider dopamine agonist in consultation with prescribing physician 1
Critical caveat: Dopamine agonists normalize prolactin in only 75% of antipsychotic-induced cases and may exacerbate underlying psychosis 1.
For asymptomatic medication-induced hyperprolactinemia: Do not treat 1.
For long-term hypogonadism (symptoms or low bone mass): Use estrogen or testosterone replacement rather than dopamine agonists 1.
Pregnancy Management
Discontinue dopamine agonists immediately upon pregnancy confirmation 1.
Exception: Continue therapy throughout pregnancy for macroadenomas that are invasive or abutting the optic chiasm, especially without prior surgery/radiation 1.
Do not measure prolactin during pregnancy 1.
Do not perform routine MRI for microadenomas or intrasellar macroadenomas unless severe headaches or visual changes occur 1.
If symptomatic tumor growth occurs during pregnancy: Restart bromocriptine 1.
Pre-pregnancy counseling: Women with macroadenomas who don't shrink on dopamine agonists or can't tolerate them should consider surgical resection before attempting pregnancy 1.
Risk of Tumor Growth During Pregnancy:
- Microprolactinomas: <5% risk 2
- Macroadenomas: Higher risk, especially without prior treatment
Key Pitfalls to Avoid
- Don't perform dynamic prolactin testing—a single elevated level suffices 1
- Don't miss the hook effect in large tumors with unexpectedly low prolactin 1
- Don't rush to surgery for drug-resistant cases—maximize cabergoline dose first 1
- Don't use dopamine agonists liberally in antipsychotic-induced hyperprolactinemia—risk of psychosis exacerbation outweighs benefits 1
- Don't continue dopamine agonists in most pregnant women—tumor growth risk is low for microadenomas 1